Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:LENZ NASDAQ:SNDX NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.10-4.9%$2.55$1.28▼$7.85$358.23M1.362.28 million shs2.17 million shsLENZLENZ Therapeutics$38.79-16.1%$40.33$16.53▼$50.40$1.32B0.5552,116 shs3.92 million shsSNDXSyndax Pharmaceuticals$16.06-0.9%$15.25$8.58▼$22.50$1.40B0.682.03 million shs2.70 million shsSTOKStoke Therapeutics$30.19+1.0%$20.97$5.35▼$32.40$1.64B1.241.23 million shs1.33 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+3.49%+4.82%+53.77%+26.36%-53.09%LENZLENZ Therapeutics-4.84%-4.28%+15.94%+33.32%+89.16%SNDXSyndax Pharmaceuticals-1.82%+4.92%+1.69%+68.93%-11.57%STOKStoke Therapeutics-1.97%+20.47%+35.48%+152.11%+150.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.10-4.9%$2.55$1.28▼$7.85$358.23M1.362.28 million shs2.17 million shsLENZLENZ Therapeutics$38.79-16.1%$40.33$16.53▼$50.40$1.32B0.5552,116 shs3.92 million shsSNDXSyndax Pharmaceuticals$16.06-0.9%$15.25$8.58▼$22.50$1.40B0.682.03 million shs2.70 million shsSTOKStoke Therapeutics$30.19+1.0%$20.97$5.35▼$32.40$1.64B1.241.23 million shs1.33 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+3.49%+4.82%+53.77%+26.36%-53.09%LENZLENZ Therapeutics-4.84%-4.28%+15.94%+33.32%+89.16%SNDXSyndax Pharmaceuticals-1.82%+4.92%+1.69%+68.93%-11.57%STOKStoke Therapeutics-1.97%+20.47%+35.48%+152.11%+150.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.40Hold$12.50303.23% UpsideLENZLENZ Therapeutics 2.67Moderate Buy$52.8036.12% UpsideSNDXSyndax Pharmaceuticals 2.82Moderate Buy$39.22144.22% UpsideSTOKStoke Therapeutics 3.00Buy$27.43-9.15% DownsideCurrent Analyst Ratings BreakdownLatest ANNX, STOK, LENZ, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$67.0010/10/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $35.0010/8/2025ANNXAnnexonWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LENZLENZ TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025STOKStoke TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025ANNXAnnexonWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LENZLENZ TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025STOKStoke TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/19/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/ASNDXSyndax Pharmaceuticals$23.68M58.42N/AN/A$3.38 per share4.75STOKStoke Therapeutics$36.56M45.25N/AN/A$4.32 per share6.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%11/13/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8535.52N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)Latest ANNX, STOK, LENZ, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025LENZLENZ Therapeutics-$0.67N/AN/AN/AN/AN/A11/4/2025Q3 2025SNDXSyndax Pharmaceuticals-$0.73N/AN/AN/A$49.08 millionN/A11/4/2025Q3 2025STOKStoke Therapeutics-$0.56N/AN/AN/AN/AN/A8/14/2025Q2 2025ANNXAnnexon-$0.36-$0.34+$0.02-$0.34N/AN/A8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 million7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.675.67LENZLENZ TherapeuticsN/A20.5420.54SNDXSyndax Pharmaceuticals2.064.714.55STOKStoke TherapeuticsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ALENZLENZ Therapeutics54.32%SNDXSyndax PharmaceuticalsN/ASTOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%LENZLENZ Therapeutics6.90%SNDXSyndax Pharmaceuticals4.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.89 million96.84 millionOptionableLENZLENZ Therapeutics11028.52 million26.55 millionN/ASNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableANNX, STOK, LENZ, and SNDX HeadlinesRecent News About These CompaniesNeedham Maintains Stoke Therapeutics (STOK) Buy Recommendation3 hours ago | msn.comWhat 4 Analyst Ratings Have To Say About Stoke Therapeutics3 hours ago | benzinga.comStoke Therapeutics price target raised to $35 from $22 at NeedhamOctober 10 at 1:30 PM | msn.comBiogen, Stoke Therapeutics present follow-up analyses from zorevunersen studiesOctober 10 at 8:29 AM | msn.comWhy Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet SyndromeOctober 10 at 8:29 AM | finance.yahoo.comWhat is Leerink Partnrs' Estimate for STOK FY2027 Earnings?October 10 at 8:15 AM | marketbeat.comBiogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying ...October 9 at 8:04 PM | markets.businessinsider.comStoke, Biogen presents new data from OLE studies of zorevunersenOctober 9 at 8:04 PM | msn.comStoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying ...October 9 at 8:04 PM | finance.yahoo.comStoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?October 9 at 10:25 AM | zacks.comStoke Therapeutics (NASDAQ:STOK) Given "Sell (D+)" Rating at Weiss RatingsOctober 9 at 2:27 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Here's WhyOctober 8 at 2:10 PM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $250,700.00 in StockOctober 8 at 5:21 AM | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from AnalystsOctober 8 at 2:55 AM | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from AnalystsOctober 8 at 2:54 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 10,000 SharesOctober 7 at 6:48 PM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Director Sells 42,461 SharesOctober 7 at 6:47 PM | marketbeat.comStoke Therapeutics stock rises after appointing Ian Smith as CEOOctober 6, 2025 | investing.comStoke Therapeutics Appoints Smith as Permanent CEOOctober 6, 2025 | marketwatch.comStoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High - Still a Buy?October 6, 2025 | marketbeat.comStoke Therapeutics Appoints Ian F. Smith as Chief Executive OfficerOctober 6, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANNX, STOK, LENZ, and SNDX Company DescriptionsAnnexon NASDAQ:ANNX$3.10 -0.16 (-4.91%) Closing price 04:00 PM EasternExtended Trading$3.15 +0.05 (+1.58%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.LENZ Therapeutics NASDAQ:LENZ$38.79 -7.46 (-16.13%) Closing price 04:00 PM EasternExtended Trading$40.31 +1.52 (+3.93%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Syndax Pharmaceuticals NASDAQ:SNDX$16.06 -0.14 (-0.86%) Closing price 04:00 PM EasternExtended Trading$15.94 -0.11 (-0.72%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Stoke Therapeutics NASDAQ:STOK$30.19 +0.29 (+0.97%) Closing price 04:00 PM EasternExtended Trading$29.32 -0.87 (-2.87%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
